Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254967 | 0.85 | TAAR1 (0.45) | HMGCRMAPK1TAAR1KDM4EGAA | |
| SCHEMBL13469242 | 0.84 | LCK (0.58) | HMGCRMAPK1CYP3A4KDM4EGAA | |
| SCHEMBL3339981 | 0.83 | CYP3A4 (0.44) | HMGCRMAPK1TAAR1CYP3A4KDM4E | |
| SCHEMBL13469255 | 0.82 | KDM4E (0.59) | HMGCRMAPK1CYP3A4KDM4EGAA | |
| SCHEMBL28285146 | 0.81 | CYP3A4 (0.61) | HMGCRMAPK1CYP3A4KDM4EGAA | |
| SCHEMBL13469397 | 0.79 | KMT2A (0.53) | HMGCRMAPK1KDM4EGAAALDH1A1 | |
| SCHEMBL30927117 | 0.79 | CYP3A4 (0.45) | HMGCRMAPK1TAAR1CYP3A4KDM4E | |
| SCHEMBL25627616 | 0.78 | HTR2A (0.43) | MAPK1TAAR1CYP3A4KDM4EGAA | |
| SCHEMBL13868273 | 0.78 | TAAR1 (0.58) | HMGCRTAAR1CYP3A4KDM4E | |
| SCHEMBL28576535 | 0.78 | HTT (0.68) | HMGCRMAPK1CYP3A4KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | HMGCR 4729/4885MAPK1 1397/4885TAAR1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.